JADO Technologies, the leading developer of novel cell membrane-targeted drugs, today announced the appointment of Charl van Zyl as its new Chief Executive Officer. Charl van Zyl will take over from Dr. Gary Jennings, cofounder and former CEO/CSO, who will continue as Chief Scientific Officer.
